The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Eytan M. Stein(Memorial Sloan Kettering Cancer Center)
Cited by 450
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
|Blood|2018|457
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
|Journal of Clinical Oncology|2021|333